Navigation Links
Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
Date:8/11/2009

looking forward to presenting our data to the Committee in support of Onrigin for its use as a new therapeutic agent for elderly poor-risk AML patients."

The Company reported ending the quarter with $26.1 million in cash and cash equivalents. Based on its current operating plan, management estimates that its existing cash and cash equivalents will be sufficient to fund operations through the second quarter of 2010. The Company's current operating plan assumes that Onrigin will be approved by the FDA in the fourth quarter of 2009 and has limited funds available for commercialization. If Onrigin is approved, the Company will either have to partner with another pharmaceutical company or raise additional capital for the commercialization of Onrigin.

Conference Call

The Company will hold a conference call at 8:30 a.m. Eastern Time on August 13, 2009 to discuss its operations and financial results.

To participate in the conference call, please dial (800) 901-5241 in the U.S. ((617) 786-2963 for international callers) at least 15 minutes before the start of the call. When prompted for a pass code, please enter 60356125.

An audio webcast of the call will be accessible at www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at

(888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 78450067. The replay will be available through August 27, 20009.


'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... York (PRWEB) September 15, 2014 Transvaginal ... Inc. continue to move forward in the federal multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... Final Order on September 10th that provides for the ... notes that none of the affected plaintiffs has objected ...
(Date:9/15/2014)... MONDAY, Sept. 15, 2014 (HealthDay News) -- U.S. heart ... an electrocardiogram (ECG) when evaluating young people for underlying ... The American Heart Association and the American College ... more detailed personal and family medical history along with ... genetic or congenital (existing from birth) risks for sudden ...
(Date:9/15/2014)... the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer ... affecting both the front and the crown of their ... risk of developing aggressive prostate cancer (usually indicates a ... non-aggressive prostate cancer) later in life, compared to men ... other patterns of baldness and prostate cancer risk. The ...
(Date:9/15/2014)... 2014 - An estimated 8% of Americans will suffer ... during their lifetime. Brought on by an overwhelming or ... altered chemistry and physiology of the brain. Understanding how ... altered by PTSD is essential to developing effective interventions. ... at The University of Texas at Dallas published online ...
(Date:9/15/2014)... FL (PRWEB) September 15, 2014 The ... away from putting low-level offenders in jail and prison ... Group sees this shift as a positive change. , ... prescription drug and heroin abuse. According to an ... parties are calling for a shift away from using ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2Health News:EEG study findings reveal how fear is processed in the brain 2Health News:White House Shifts Policy on Drugs 2
... body of basic animal research and studies of abused ... for the hypothesis that individuals with particular genotypes are ... with the abuse of alcohol and other substances. ... assume that these genotypes identify people who are predestined ...
... Board of Directors Audit Committee Members and Complies with ... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... J. Wilson as vice president of finance and principal ... team. She brings over twenty years of finance ...
... of Suntan Lotions, Reducing Risk of Deadly Skin Cancer ... & Prevention MonthNEW YORK, April 29 The ... people avoid overexposure to harmful ultraviolet radiation from the ... all across America reduce the risk of skin cancer ...
... 23-month-old child in Texas; CDC warns more deaths are ... 23-month-old child in Texas has become the first U.S. ... officials said Wednesday morning. , Dr. Richard Besser, acting ... Prevention, confirmed the death. No other details on the ...
... Dr. Gordon Norman presents overview of US healthcare ... Federation of Health Plans Meeting in Boston- Noted ... value for its healthcare investment- Emphasized greater coordination ... resolve today,s healthcare challenges MARIETTA, Ga., April 29 ...
... & Mentally IllNEW YORK, April 29 May marks ... it, philanthropic-minded New Yorkers will raise money for Weston ... and physically disabled. As federal and state funding ... the current economy, supporters will raise funds amidst live ...
Cached Medicine News:Health News:Genetic risk for anxiety does not have to be destiny 2Health News:PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 3Health News:U.S. Reports First Swine Flu Death 2Health News:U.S. Reports First Swine Flu Death 3Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 2Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 3Health News:Weston United Celebrates Mental Health Month on May 19th 2
(Date:9/15/2014)... -- MedicOne Medical Response, a leading provider emergency ... by Inc. Magazine as one of the fastest ... Photo - http://photos.prnewswire.com/prnh/20140914/145997 ... companies with the largest revenue growth between 2010 ... two ambulance companies to make the list, achieved ...
(Date:9/15/2014)...  Catalist-listed QT Vascular Ltd. ("QT Vascular" or together ... of minimally invasive medical devices for the treatment of ... has enrolled the first European patients in the ENDURE ... have already been enrolled in this study with Dr. ... Auckland, New Zealand . ...
(Date:9/15/2014)... , Sept. 15, 2014  Over 200 patients, ... roof Saturday to learn, interact and participate in ... City,s first Lupus Trials Fair launched by the ... S.L.E. Lupus Foundation .  Attendees interacted directly ... -- sharing experiences, ideas and needs and learning ...
Breaking Medicine Technology:MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3
... ROCHESTER, N.Y., Sept. 8 VirtualScopics, Inc. (Nasdaq: ... for clinical trials, announced today that Ms. Molly Henderson, ... presenting a corporate overview at the Rodman & Renshaw ... City. Ms. Henderson,s presentation will be on Tuesday, September ...
... N.J., Sept. 8 Today every major pharmaceutical industry ... the future of pharma.  In an unprecedented move, they,re ... the big names in pharma.  All in one place. ... at the Pharma CI Conference & Exhibition at the ...
Cached Medicine Technology:VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference 2Pharmaceutical Industry Insiders, VIPs All Coming Together for Future of Pharma Market, Pharmaceutical Competitive Intelligence 2
... The Driver Stent design, utilizing ... the limitations of stainless steel ... possible thinner struts, for unparalleled ... The Driver Coronary Stent Systemwith ...
... Guiding Catheter provides support to enhance ... under adverse conditions. It gives you ... to your destination in cardiac interventions. ... variety of clinical situations and the ...
... Catheters are intended for use ... applications. They provide a pathway ... as balloon dilatation catheters, guide ... may be introduced. These devices ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
Medicine Products: